Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | GBA1 | P04062 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.48 |
| ▸ | RAD52 | P43351 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9619069 | 0.85 | MEN1 (0.49) | ALDH1A1KDM4ETSHRMEN1KMT2A | |
| SCHEMBL8049805 | 0.85 | GBA1 (0.70) | CYP1A2CYP2D6CYP2C9CYP2C19GBA1 | |
| SCHEMBL9619145 | 0.84 | GAA (0.50) | CYP1A2CYP2C9CYP2C19ALDH1A1KDM4E | |
| SCHEMBL9618999 | 0.83 | KDM4E (0.51) | ALDH1A1KDM4ETSHRMEN1KMT2A | |
| SCHEMBL9619183 | 0.82 | KDM4E (0.50) | GBA1ALDH1A1KDM4ETSHRMEN1 | |
| SCHEMBL9619057 | 0.82 | KDM4E (0.50) | GBA1ALDH1A1KDM4ETSHRMEN1 | |
| SCHEMBL9619060 | 0.82 | KDM4E (0.50) | GBA1ALDH1A1KDM4ETSHRMEN1 | |
| SCHEMBL9619171 | 0.82 | SMN1; SMN2 (0.57) | ALDH1A1KDM4ETSHRMEN1KMT2A | |
| SCHEMBL9619263 | 0.82 | ALDH1A1 (0.50) | ALDH1A1KDM4ETSHRMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL10418857 | 0.81 | SMN1; SMN2 (0.56) | ALDH1A1KDM4ETSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0356412-B1 | USE OF 2-AMINO-4-MORPHOLINO-6-PROPYL-1,3,5-TRIAZINES IN THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF COGNITIVE AND MENTAL DISORDERS | U C B, S.A. (BE) | 1992-05-13 | — | — | EP | claimed |
| EP-0356413-B1 | 2-AMINO-4-MORPHOLINO-6-PROPYL-1,3,5-TRIAZINES | U C B, S.A. (BE) | 1992-01-29 | — | — | EP | claimed |
| US-4956363-A | 2-amino-4-morpholino-6-propyl-1,3,5-triazine | U C B S.A. (BE) | 1990-09-11 | — | — | US | claimed |
| US-4956367-A | COGNITION ACTIVATORS, ALZHEIMER*S DISEASE | U C B S.A. (BE) | 1990-09-11 | — | — | US | claimed |
| EP-0356412-A1 | Use of 2-amino-4-morpholino-6-propyl-1,3,5-triazines in the preparation of a medicament for the treatment of cognitive and mental disorders | U C B, S.A. (BE) | 1990-02-28 | — | — | EP | claimed |
| EP-0356413-A1 | 2-Amino-4-morpholino-6-propyl-1,3,5-triazines | U C B, S.A. (BE) | 1990-02-28 | — | — | EP | claimed |
| JP-2108675-A | — | — | None | — | — | JP | disclosed |
| US-20100092479-A1 | Compositions and methods for treatment of viral diseases | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-04-15 | — | — | US | disclosed |
| WO-2010021681-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-02-25 | — | — | WO | disclosed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20090053168-A1 | TREATMENTS OF B-CELL PROLIFERATIVE DISORDERS | ZALICUS INC. | 2009-02-26 | — | — | US | disclosed |
| US-20090047243-A1 | COMBINATIONS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS | ZALICUS INC. | 2009-02-19 | — | — | US | disclosed |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) | 2008-07-03 | — | — | US | disclosed |
| EP-0356412-B1 | USE OF 2-AMINO-4-MORPHOLINO-6-PROPYL-1,3,5-TRIAZINES IN THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF COGNITIVE AND MENTAL DISORDERS | U C B, S.A. (BE) | 1992-05-13 | — | — | EP | disclosed |
| EP-0356413-B1 | 2-AMINO-4-MORPHOLINO-6-PROPYL-1,3,5-TRIAZINES | U C B, S.A. (BE) | 1992-01-29 | — | — | EP | disclosed |
| US-4956363-A | 2-amino-4-morpholino-6-propyl-1,3,5-triazine | U C B S.A. (BE) | 1990-09-11 | — | — | US | disclosed |
| US-4956367-A | COGNITION ACTIVATORS, ALZHEIMER*S DISEASE | U C B S.A. (BE) | 1990-09-11 | — | — | US | disclosed |
| JP-H02108675-A | 2-AMINO-4-MORPHOLINO-6-PROPYL-1,3,5-TRIAZINE | UCB SA | 1990-04-20 | — | — | JP | disclosed |
| EP-0356412-A1 | Use of 2-amino-4-morpholino-6-propyl-1,3,5-triazines in the preparation of a medicament for the treatment of cognitive and mental disorders | U C B, S.A. (BE) | 1990-02-28 | — | — | EP | disclosed |
| EP-0356413-A1 | 2-Amino-4-morpholino-6-propyl-1,3,5-triazines | U C B, S.A. (BE) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | CYP1A2 588/4885CYP2D6 650/4885CYP2C9 1449/4885 |
| US-20090047243-A1 | COMBINATIONS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS | ADORA2A, PDE4A, PDE4D | CYP1A2 3317/4885CYP2D6 3886/4885CYP2C9 4671/4885 |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, EIF2AK2, RNASE1 | CYP1A2 1154/4885CYP2D6 1538/4885CYP2C9 2233/4885 |
| US-20100092479-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, RNASE1, EIF2AK2 | CYP1A2 1420/4885CYP2D6 2122/4885CYP2C9 2071/4885 |
| US-20090053168-A1 | TREATMENTS OF B-CELL PROLIFERATIVE DISORDERS | BCL6, BCL6B, BCL3 | CYP1A2 3883/4885CYP2D6 4553/4885CYP2C9 4865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.